Teri Woodwick Sides - 19 Nov 2025 Form 4 Insider Report for SURMODICS INC (SRDX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
19 Nov 2025, 18:14:23 UTC
Prior SEC filing
06 Dec 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John Manders on behalf of Teryl L.W. Sides

Key filing fact

Teri Woodwick Sides filed Form 4 for SURMODICS INC (SRDX) on 19 Nov 2025.

Key facts

  • This page summarizes Teri Woodwick Sides's Form 4 filing for SURMODICS INC (SRDX).
  • 9 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 19 Nov 2025, 18:14.

Change

  • Previous filing in this sequence was filed on 06 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001758749 Primary reporting owner

SIDES TERI WOODWICK

Relationship
SVP, Vascular Interventions
Address
9924 WEST 74TH STREET, EDEN PRAIRIE
Signature
/s/ John Manders on behalf of Teryl L.W. Sides
Signature date
19 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SRDX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares
-34,703
Change %
-100%
Price
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-5,463
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
5,463
Exercise price
$56.63
Footnotes
F3
SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-12,292
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,292
Exercise price
$56.63
Footnotes
F3
SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-8,356
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,356
Exercise price
$42.00
Footnotes
F3
SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-15,668
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,668
Exercise price
$42.00
Footnotes
F3
SRDX transaction Derivative

Employee Stock Options (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-17,883
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,883
Exercise price
$37.44
Footnotes
F3
SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-18,337
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,337
Exercise price
$43.93
Footnotes
F3
SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-28,864
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
28,864
Exercise price
$36.13
Footnotes
F3
SRDX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
$0
Shares
-29,582
Change %
-100%
Price
$0.000000
Shares after
0
Date
19 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
29,582
Exercise price
$33.64
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Teri Woodwick Sides is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to that certain Merger Agreement, dated as of May 28, 2024, by and among the Surmodics, Inc. (the "Issuer"), BCE Parent, LLC, ("Parent"), and BCE Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock, par value $0.05 per share ("Common Stock"), that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). All outstanding restricted stock units ("RSUs") held by the reporting person vested immediately prior to the Effective Time and the reporting person is entitled to receive the Merger Consideration for such vested RSUs.

Footnote F2

As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Common Stock.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .